{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:19:37Z","timestamp":1788585577358,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00520-021-06543-9","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T07:03:01Z","timestamp":1632207781000},"page":"2839-2851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review"],"prefix":"10.1007","volume":"30","author":[{"given":"Nolan J.","family":"Maloney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C.","family":"Zaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9677-9332","authenticated-orcid":false,"given":"Bernice Y.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"issue":"1","key":"6543_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372(1):30\u201339","journal-title":"N Engl J Med"},{"issue":"8","key":"6543_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R et al (2016) Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 34(8):871\u2013878","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"issue":"4","key":"6543_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","volume":"17","author":"DG Coit","year":"2019","unstructured":"Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C et al (2019) Cutaneous melanoma, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw\u202f: JNCCN 17(4):367\u2013402","journal-title":"J Natl Compr Canc Netw\u202f: JNCCN"},{"issue":"11","key":"6543_CR4","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480\u20131492","journal-title":"Lancet Oncol"},{"issue":"30","key":"6543_CR5","first-page":"5036213","volume":"2018","author":"I Russo","year":"2018","unstructured":"Russo I, Zorzetto L, Chiarion Sileni V, Alaibac M (2018) Cutaneous side effects of targeted therapy and immunotherapy for advanced melanoma. Scientifica 2018(30):5036213","journal-title":"Scientifica"},{"issue":"2","key":"6543_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/jdv.13443","volume":"30","author":"L Peuvrel","year":"2016","unstructured":"Peuvrel L, Qu\u00e9reux G, Saint-Jean M, Brocard A, Nguyen JM, Khammari A et al (2016) Profile of vemurafenib-induced severe skin toxicities. J Eur Acad Dermatol Venereol 30(2):250\u2013257","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"6543_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"issue":"9","key":"6543_CR8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1056\/NEJMc1114329","volume":"366","author":"JJ Harding","year":"2012","unstructured":"Harding JJ, Pulitzer M, Chapman PB (2012) Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med 366(9):866\u2013868","journal-title":"N Engl J Med"},{"issue":"5","key":"6543_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/CMR.0000000000000472","volume":"28","author":"M Lamiaux","year":"2018","unstructured":"Lamiaux M, Scalbert C, Lepesant P, Desmedt E, Templier C, Dziwniel V et al (2018) Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. Melanoma Res 28(5):451\u2013457","journal-title":"Melanoma Res"},{"issue":"6","key":"6543_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1158\/2326-6066.CIR-13-0092","volume":"1","author":"DB Johnson","year":"2013","unstructured":"Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG et al (2013) Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res 1(6):373\u2013377","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"6543_CR11","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1111\/jdv.13331","volume":"30","author":"K Imafuku","year":"2016","unstructured":"Imafuku K, Yoshino K, Ishiwata K, Otobe S, Tsuboi S, Ohara K et al (2016) Severe rash associated with vemurafenib administration following nivolumab therapy. J Eur Acad Dermatol Venereol 30(10):e84\u2013e86","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"6543_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/1346-8138.13489","volume":"44","author":"S Tsuboi","year":"2017","unstructured":"Tsuboi S, Yoshino K, Yamaguchi K, Imafuku K, Ohara K (2017) Two cases of successful treatment for severe skin rash induced by vemurafenib following nivolumab therapy without cessation of vemurafenib. J Dermatol 44(5):607\u2013608","journal-title":"J Dermatol"},{"issue":"1","key":"6543_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-018-0475-y","volume":"7","author":"AR Naqash","year":"2019","unstructured":"Naqash AR, File DM, Ziemer CM, Whang YE, Landman P, Googe PB et al (2019) Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF\/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. J Immunother Cancer 7(1):4","journal-title":"J Immunother Cancer"},{"issue":"7","key":"6543_CR14","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/annonc\/mdx187","volume":"28","author":"M Urosevic-Maiwald","year":"2017","unstructured":"Urosevic-Maiwald M, Mangana J, Dummer R (2017) Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma. Ann Oncol England 28(7):1673\u20131675","journal-title":"Ann Oncol\u202f: official journal of the European Society for Medical Oncology. England"},{"issue":"2","key":"6543_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jaad.2018.07.029","volume":"80","author":"B Br\u00e9geon","year":"2019","unstructured":"Br\u00e9geon B, Bernier C, Josselin N, Peuvrel L, Le Moigne M, Saint-Jean M et al (2019) Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: a series of 11 cases. J Am Acad Dermatol 80(2):558\u2013562","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"6543_CR16","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1111\/jdv.13892","volume":"31","author":"K Imafuku","year":"2017","unstructured":"Imafuku K, Yoshino K, Ymaguchi K, Tsuboi S, Ohara K, Hata H (2017) Nivolumab therapy before vemurafenib administration induces a severe skin rash. J Eur Acad Dermatol Venereol 31(3):e169\u2013e171","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"6543_CR17","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1111\/ijd.14852","volume":"59","author":"C Olteanu","year":"2020","unstructured":"Olteanu C, Scope A, Steinberg-Silman Y, Ziv M, Shear NH, Dodiuk-Gad RP et al (2020) Vemurafenib-induced DRESS\/DIHS resulting in spontaneous melanoma regression: an immunological reaction shedding new light on melanoma treatment? Int J Dermatol 59(5):e139\u2013e141","journal-title":"Int J Dermatol"},{"key":"6543_CR18","doi-asserted-by":"crossref","unstructured":"Maximova N, Maestro A, Zanon D, Marcuzzi A (2020) Rapid recovery of postnivolumab vemurafenib-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome after tocilizumab and infliximab administration. J Immunother Cancer [Internet]. [cited 2020 Sep 27];8(1). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7057420\/","DOI":"10.1136\/jitc-2019-000388"},{"issue":"5","key":"6543_CR19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jdcr.2019.02.033","volume":"5","author":"C Luherne","year":"2019","unstructured":"Luherne C, Darrigade A-S, Dutriaux C, Prey S, Milpied B (2019) Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: not always safe! JAAD Case Rep 5(5):422\u2013423","journal-title":"JAAD Case Rep"},{"key":"6543_CR20","doi-asserted-by":"publisher","first-page":"bcr2018224379","DOI":"10.1136\/bcr-2018-224379","volume":"2018","author":"J Ros","year":"2018","unstructured":"Ros J, Munoz-Couselo E (2018) DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem. BMJ Case Rep 2018:bcr2018224379","journal-title":"BMJ Case Rep"},{"issue":"6","key":"6543_CR21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jdcr.2017.06.027","volume":"3","author":"C Pinard","year":"2017","unstructured":"Pinard C, Mignard C, Samain A, Duval-Modeste A-B, Joly P (2017) Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib. JAAD Case Rep 3(6):532\u2013533","journal-title":"JAAD Case Rep"},{"issue":"1","key":"6543_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000439272","volume":"232","author":"M Munch","year":"2016","unstructured":"Munch M, Peuvrel L, Brocard A, Saint Jean M, Khammari A, Dreno B et al (2016) Early-onset vemurafenib-induced DRESS syndrome. Dermatology 232(1):126\u2013128","journal-title":"Dermatology"},{"issue":"1","key":"6543_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/jdv.12685","volume":"30","author":"A Gey","year":"2016","unstructured":"Gey A, Milpied B, Dutriaux C, Mateus C, Robert C, Perro G et al (2016) Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction? J Eur Acad Dermatol Venereol 30(1):178\u2013179","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"6543_CR24","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamadermatol.2013.5278","volume":"149","author":"KS Wenk","year":"2013","unstructured":"Wenk KS, Pichard DC, Nasabzadeh T, Jang S, Venna SS (2013) Vemurafenib-induced DRESS. JAMA Dermatol 149(10):1242\u20131243","journal-title":"JAMA Dermatol"},{"issue":"5","key":"6543_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1310\/hpj4905-420","volume":"49","author":"MA Mancano","year":"2014","unstructured":"Mancano MA (2014) Vigabatrin-induced encephalopathy; fidaxomicin hypersensitivity reactions; vemurafenib-induced DRESS; severe alkalosis and hypokalemia with stanozolol misuse; isotretinoin-associated lip abscess; eltrombopag-associated hyperpigmentation. Hosp Pharm 49(5):420\u2013424","journal-title":"Hosp Pharm"},{"issue":"6","key":"6543_CR26","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/all.12410","volume":"69","author":"T Ishida","year":"2014","unstructured":"Ishida T, Kano Y, Mizukawa Y, Shiohara T (2014) The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome. Allergy 69(6):798\u2013805","journal-title":"Allergy"},{"issue":"3","key":"6543_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jtho.2019.12.121","volume":"15","author":"D De-Rui Huang","year":"2020","unstructured":"De-Rui Huang D, Chih-Hsin YJ (2020) Checkpoint inhibitor combined with tyrosine kinase inhibitor\u2014the end or beginning? J Thorac Oncol 15(3):305\u2013307","journal-title":"J Thorac Oncol"},{"issue":"1","key":"6543_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","volume":"14","author":"JJ Lin","year":"2019","unstructured":"Lin JJ, Chin E, Yeap BY, Ferris LA, Kamesan V, Lennes IT et al (2019) Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non\u2013small cell lung cancer. J Thorac Oncol 14(1):135\u2013140","journal-title":"J Thorac Oncol"},{"issue":"1","key":"6543_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2326-6066.CIR-13-0160","volume":"2","author":"MK Callahan","year":"2014","unstructured":"Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S et al (2014) Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res 2(1):70\u201379","journal-title":"Cancer Immunol Res"},{"issue":"20","key":"6543_CR30","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867\u20131876","journal-title":"N Engl J Med"},{"issue":"18","key":"6543_CR31","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694\u20131703","journal-title":"N Engl J Med"},{"issue":"2","key":"6543_CR32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/j.1365-2133.2006.07284.x","volume":"155","author":"H Peyriere","year":"2006","unstructured":"Peyriere H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac J-P et al (2006) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 155(2):422\u2013428","journal-title":"Br J Dermatol"},{"issue":"1","key":"6543_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/ijd.IJD_582_17","volume":"63","author":"A De","year":"2018","unstructured":"De A, Rajagopalan M, Sarda A, Das S, Biswas P (2018) Drug reaction with eosinophilia and systemic symptoms: an update and review of recent literature. Indian J Dermatol 63(1):30\u201340","journal-title":"Indian J Dermatol"},{"key":"6543_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4166\/kjg.2016.67.6.337","volume":"67","author":"DK Kim","year":"2016","unstructured":"Kim DK, Lee SW, Nam HS, Jeon DS, Park NR, Nam YH et al (2016) A case of sorafenib-induced DRESS syndrome in hepatocelluar carcinoma. Korean J Gastroenterol = Taehan Sohwagi Hakhoe chi. Korea (South) 67:337\u2013340","journal-title":"Korean J Gastroenterol = Taehan Sohwagi Hakhoe chi. Korea (South)"},{"issue":"4","key":"6543_CR35","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.apsb.2018.01.008","volume":"8","author":"F Liu","year":"2018","unstructured":"Liu F, Yang X, Geng M, Huang M (2018) Targeting ERK, an Achilles\u2019 heel of the MAPK pathway, in cancer therapy. Acta Pharm Sin B 8(4):552\u2013562","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"6543_CR36","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/bjd.15423","volume":"177","author":"NR Adler","year":"2017","unstructured":"Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MSY, Phillips EJ (2017) Recent advances in the understanding of severe cutaneous adverse reactions. Br J Dermatol 177(5):1234\u20131247","journal-title":"Br J Dermatol"},{"issue":"10","key":"6543_CR37","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1093\/annonc\/mdx325","volume":"28","author":"H Umemura","year":"2017","unstructured":"Umemura H, Yamasaki O, Morizane S, Iwatsuki K (2017) Possible macrophage activation in melanoma patients receiving combined kinase inhibitor therapy following anti-PD-1 therapy: a cytokine profiling study of two cases. Ann Oncol 28(10):2624\u20132625","journal-title":"Ann Oncol"},{"key":"6543_CR38","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/annonc\/mdy175","volume":"29","author":"K Sasaki","year":"2018","unstructured":"Sasaki K, Uehara J, Iinuma S, Doi H, Honma M, Toki Y et al (2018) Hemophagocytic lymphohistiocytosis associated with dabrafenib and trametinib combination therapy following pembrolizumab administration for advanced melanoma. Ann Oncol 29:1602\u20131603","journal-title":"Ann Oncol\u202f: official journal of the European Society for Medical Oncology. England"},{"key":"6543_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15196","author":"JJ Yang","year":"2020","unstructured":"Yang JJ, Lei DK, Ravi V, Maloney NJ, Crew A, Worswick S (2020) Overlap between hemophagocytic lymphohistiocytosis and drug reaction and eosinophilia with systemic symptoms: a review. Int J Dermatol. https:\/\/doi.org\/10.1111\/ijd.15196","journal-title":"Int J Dermatol"},{"issue":"1","key":"6543_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-018-0786-0","volume":"17","author":"GE Naoum","year":"2018","unstructured":"Naoum GE, Morkos M, Kim B, Arafat W (2018) Novel targeted therapies and immunotherapy for advanced thyroid cancers. Mol Cancer 17(1):51","journal-title":"Mol Cancer"},{"key":"6543_CR41","unstructured":"ClinicalTrials.gov (2014) DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing) a phase III trial [Internet]. Bethesda (MD): National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02224781"},{"issue":"6","key":"6543_CR42","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","volume":"25","author":"PA Ascierto","year":"2019","unstructured":"Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H et al (2019) Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med 25(6):941\u2013946","journal-title":"Nat Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06543-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06543-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06543-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T08:04:19Z","timestamp":1643270659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06543-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["6543"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06543-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]},"assertion":[{"value":"28 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}